What to do: Do not use the affected product. Return it to your local pharmacy for proper disposal. Seek medical attention if you or your child have used this product and are experiencing persistent or worsening symptoms, such as fevers, or facial pain or pressure. Consult a healthcare professional if you or your child have used this product and have health concerns.
Affected products
Product
DIN
Lot
Expiry
APO-Mometasone nasal spray, 50 mcg/metered spray
02403587
TX5343
TZ2586
Sep 2025
Oct 2025
Issue
Apotex Inc. is recalling two lots of APO-Mometasone nasal spray due to possible bacterial contamination with Burkholderia cepacia complex (Bcc). Bcc is a group of bacteria that poses a low medical risk to most healthy people; however, children, those with chronic lung diseases, people who are pregnant, seniors and those with a weakened immune system may be at a higher risk of illness.
APO-Mometasone nasal spray is a prescription drug used to treat seasonal and year-round nasal allergy symptoms (such as itchy, stuffy or runny nose and sneezing) in children 3-11 years old. It is also used to treat sinusitis (sinus inflammation) in adults and children 12 years of age and older, and nasal polyps in adults.
The effects of Bcc vary widely, ranging from no symptoms at all to serious infections. In severe cases, Bcc can lead to bloodstream infections that may result in sepsis (a serious medical condition caused by an overwhelming immune response to an infection) and death. Bcc is often resistant to common antibiotics. People experiencing persistent or worsening symptoms, such as fevers, or facial pain or pressure, should seek medical attention.
Health Canada is monitoring the company's recall and its implementation of corrective and preventative actions. Supply might be temporarily constrained as a result of this recall. You should speak to your healthcare provider about what suitable alternative treatments are available to you or your child.
What you should do
Do not use the affected product. Return it to your local pharmacy for proper disposal.
Seek medical attention if you or your child have used this product and are experiencing persistent or worsening symptoms, such as fevers, or facial pain or pressure. Consult a health care professional if you or your child have used this product and have health concerns.
Contact Apotex Inc. via Sedgwick by calling 1-844-265-7389 if you have questions about this recall.
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...
YOUR LEGAL RIGHTS MAY BE AFFECTED
There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...